BTIG analyst Ryan Zimmerman initiated NuVasive with a Buy rating and a price target of $68 after its "mixed" Q2 results. The analyst states that while the company's revenues topped consensus based on the new product adoption and higher conversion in the U.S. Spinal Hardware market, gross margins were "challenged" by manufacturing scale. Zimmerman adds that NuVasive has kept its FY18 guidance, which is "beatable considering recent implant performance", but also warns that delaying margin improvement expectations could disappoint some investors. The analyst still believes that the company's valuation is attractive given the "improving top-line dynamics".